Lung Cancer Clinical Trial
Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients
Summary
Demonstrate feasibility of detection of EML4-ALK fusion transcripts and T790M EGFR mutation from exosomes in the circulation of Non-Small Cell Lung Cancer (NSCLS) patients.
Full Description
The goal of this study is two-fold: 1) Demonstrate feasibility of detection of EML4-ALK fusion transcripts in the circulation of NSCLC patients positive for ALK on tissue analysis, using an institutionally accepted assay; 2) Demonstrate feasibility of detection of T790M EGFR mutation in the circulation of NSCLC patients positive for T790M on tissue analysis, using an institutionally accepted assay.
Eligibility Criteria
Inclusion Criteria:
Participants must have histologically confirmed NSCLC, stage IIIB- IV, and have tested positive for the presence of EML4-ALK on tissue specimen, fresh or archived, using an institutionally accepted assay.
Age of 18 years or older.
Participants are being considered for ALK-directed therapy or have progressed on EGFR TKI treatment.
Participants must have hemoglobin > 10 mg/dL.
Ability to understand and willingness to sign a written informed consent document.
Exclusion Criteria:
Hepatitis (all types) in patient's medical record
HIV documented in patient's medical record
Hemoglobin < 10 mg/dL
Less than 18 years of age
Histologically confirmed NSCLC Stage I-IIIA
Tested negative for the presence of EML4-ALK and T790M EGFR on tissue
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 2 Locations for this study
Hollywood Florida, 33021, United States
New Orleans Louisiana, 70121, United States
How clear is this clinincal trial information?